Decoding the Immune Switchpoints of Health and Disease

Immune dysfunction underlies half of human diseases - yet its mechanisms remain largely unknown.

Switchpoint Bio reveals these hidden mechanisms to transform how we understand, prevent and treat disease.

Gaps in our Understanding of Immune Biology Limit the Development of Treatments.

Preclinical models do not reflect human immune biology
Uncertainty in clinical trial outcomes reflects inadequate mechanistic stratification
Biomarkers are often correlational rather than causal
Regulators demand stronger biological rationale

Treatments are developed without a comprehensive understanding of how the human immune response evolves through stages of disease.

Turning Immune Biology Into Decision-Grade Evidence

We characterize immune cell composition and function from standard blood samples. We enable enrichment of existing cohorts with a unique immuno-epigenetic data layer that reveals mechanisms of human disease.

Reveal mechanisms of human disease

Enable biologically informed trial design

Stratify patients based on immune function

Enable early disease detection and preventive treatments

Partner with us

Identify immune-relevant drug targets
Explain response variability and guide patient stratification
Detect immune profiles across different stages of the disease

Why us?

Built by pioneers in single-cell biology, epigenetics and genomics.

Deep immune science, engineered into a scalable platform.

The future of medicine will be immune-driven. We’re building it now.

Fill in your details and we’ll get in touch!

Our Team is Based in Helsinki & Boston

Samuel
Myllykangas, PhD
CEO & Co-founder

Founder/CEO Blueprint Genetics (acquired by Quest Diagnostics).

Former VP at Quest Diagnostics.

Stanford-trained genomic scientist.

Experienced in building global, regulated genomics platforms from innovation to commercial scale.

Jussi
Paananen, PhD
CTO & Co-founder

Built Blueprint Genetics’ technology and product teams and led Global Bioinformatics at Quest.

Former technology leader at Meru Health and scientist at Broad Institute.

Experienced in delivering AI, genomics, and data platforms in regulated clinical environments.

Niilo
Färkkilä, PhD
CCO & Co-founder

Senior pharma executive with leadership experience across Amgen, GSK and Pfizer, spanning several therapy areas.

Strong background in real-world evidence, digital health and health economics.

Leads Switchpoint’s pharma partnerships and commercialization strategy.

Jason
Buenrostro, PhD
Scientific Advisor &
Co-founder

Pioneer of epigenetics and single-cell biology. Inventor of ATAC-seq.

Professor at Harvard and Director of Epigenomics at the Broad Institute.

MacArthur Fellow. Global leader in single-cell and immune epigenomics, with landmark publications in Nature, Science, and Cell.

Mitja
Kurki, PhD
Scientific Advisor &
Co-founder

Founder of FinnGen analytics and architect of a 500,000+ person genomics platform.

Broad Institute leader delivering genomics infrastructure and pharma data platforms.

Expert in population-scale genomics and drug discovery enablement.